Relapse after First-Line Fixed Duration Ibrutinib plus Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

被引：0

作者：

Ghia, Paolo ^{[1
,2
]}

Wierda, William G. ^{[3
]}

Barr, Paul M. ^{[4
]}

Kipps, Thomas J. ^{[5
]}

Siddiqi, Tanya ^{[6
]}

Allan, John N. ^{[7
]}

Hunter, Zoe ^{[8
]}

Zhou, Cathy ^{[8
]}

Szoke, Anita ^{[8
]}

Dean, James P. ^{[9
,10
]}

Tam, Constantine S. ^{[11
,12
]}

机构：

[1] Univ Vita Salute San Raffaele, Milan, Italy

[2] IRCCS Osped San Raffaele, Milan, Italy

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY USA

[5] UC San Diego Moores Canc Ctr, Duarte, CA USA

[6] City Hope Natl Med Ctr, Duarte, CA USA

[7] Weill Cornell Med, Long Isl City, NY USA

[8] AbbVie, N Chicago, IL USA

[9] AbbVie, IMBRUVICA, N Chicago, IL USA

[10] AbbVie, Pediat Oncol, N Chicago, IL USA

[11] Alfred Hosp, Melbourne, Vic, Australia

[12] Monash Univ, Melbourne, Vic, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187128

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)
Burger, Jan A.
Robak, Tadeusz
Demirkan, Fatih
Bairey, Osnat
Moreno, Carol
Simpson, David
Munir, Talha
Stevens, Don A.
Dai, Sandra
Cheung, Leo W. K.
Kwei, Kevin
Lal, Indu
Hsu, Emily
Kipps, Thomas J.
Tedeschi, Alessandra
BLOOD, 2020, 136
[22] Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study
Cramer, P.
Fraser, G.
Chanan-Khan, A.
Demirkan, F.
Silva, Santucci R.
Pylypenko, H.
Grosicki, S.
Janssens, A.
Pristupa, A.
Mayer, J.
Dilhuydy, M. -S
Loscertales, J.
Goy, A.
Avigdor, A.
Rule, S.
Phelps, C.
Mahler, M.
Salman, M.
Howes, A.
Balasubramanian, S.
Hallek, M.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 34 - 35
[23] Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Barr, Paul M.
Owen, Carolyn
Robak, Tadeusz
Tedeschi, Alessandra
Bairey, Osnat
Burger, Jan Andreas
Hillmen, Peter
Coutre, Steve E.
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Li, Jianyong
Simpson, David
Offner, Fritz C.
Moreno, Carol
Dai, Sandra
Szoke, Anita
Dean, James P.
Kipps, Thomas J.
Ghia, Paolo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)
Burger, Jan
Barr, Paul
Owen, Carolyn
Robak, Tadeusz
Tedeschi, Alessandra
Bairey, Osnat
Hillmen, Peter
Coutre, Steve
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Li, Jianyong
Offner, Fritz
Moreno, Carol
Dai, Sandra
Szoke, Anita
Dean, James P.
Kipps, Thomas J.
Ghia, Paolo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S316 - S316
[25] Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
Moreno, Carol
Greil, Richard
Demirkan, Fatih
Tedeschi, Alessandra
Anz, Bertrand
Larratt, Loree
Simkovic, Martin
Samoilova, Olga
Novak, Jan
Ben-Yehuda, Dina
Strugov, Vladimir
Gill, Devinder
Gribben, John G.
Hsu, Emily
Zhou, Cathy
Clow, Fong
James, Danelle F.
Styles, Lori
Flinn, Ian W.
BLOOD, 2018, 132
[26] A PHASE 2 STUDY OF THE BTK INHIBITOR IBRUTINIB IN GENETIC RISK-STRATIFIED RELAPSED AND REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Maddocks, K.
Flynn, J. M.
Andritsos, L. A.
Awan, F.
Woyach, J. A.
Grever, M. R.
Stefanos, M.
Lynch, J.
Johnson, A. J.
Byrd, J. C.
Jones, J. A.
HAEMATOLOGICA, 2014, 99 : 522 - 522
[27] IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY
Fraser, G.
Cramer, P.
Demirkan, F.
Santucci Silva, R.
Grosicki, S.
Janssens, A.
Mayer, J.
Dilhuydy, M. S.
Pylypenko, H.
Loscertales, J.
Goy, A.
Avigdor, A.
Rule, S.
Phelps, C.
Mahler, M.
Salman, M.
Howes, A.
Hallek, M.
HAEMATOLOGICA, 2016, 101 : 150 - 151
[28] Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.
Fraser, Graeme
Cramer, Paula
Demirkan, Fatih
Silva, Rodrigo Santucci
Pylypenko, Halyna
Grosicki, Sebastian
Janssens, Ann
Pristupa, Aleksander
Mayer, Jiri
Dilhuydy, Marie-Sarah
Loscertales, Javier
Goy, Andre
Avigdor, Abraham
Rule, Simon
Phelps, Charles
Mahler, Michelle
Salman, Mariya
Howes, Angela J.
Balasubramanian, Sriram
Chanan-Khan, Asher Alban Akmal
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[29] Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
Wierda, William G.
Tam, Constantine S.
Allan, John N.
Siddiqi, Tanya
Kipps, Thomas J.
Opat, Stephen
Tedeschi, Alessandra
Badoux, Xavier C.
Kuss, Bryone J.
Jackson, Sharon
Moreno, Carol
Jacobs, Ryan
Pagel, John M.
Flinn, Ian W.
Zhou, Cathy
Szafer-Glusman, Edith
Ninomoto, Joi
Dean, James P.
James, Danelle F.
Ghia, Paolo
BLOOD, 2020, 136
[30] Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
O'Brien, Susan M.
Jones, Jeffrey A.
Furman, Richard R.
Coutre, Steven E.
Flinn, Ian W.
Burger, Jan A.
Blum, Kristie A.
Sharman, Jeff P.
Wierda, William G.
Zhao, Weiqiang
Heerema, Nyla A.
Johnson, Amy J.
Tran, Anh
Zhou, Cathy
Bilotti, Elizabeth
James, Danelle F.
Byrd, John C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S206

← 1 2 3 4 5 →